The effective treatment of COPD: Anticholinergics and what else?

Emerging drugs in chronic obstructive pulmonary disease

“…The differences in study results may be due to the type of LABA. This may be the reason that several companies prefer to create fixed combinations with LAMA and formoterol [84] . Nonetheless, there are continuing trials exploring the effects of a combination of tiotropium and salmeterol.…”

“…Administration of the triple combination improved trough FEV1 to a greater extent than ICS + LABA or LAMA alone [84] . Another study analyzed 1 year of treatment with tiotropium plus placebo, tiotropium plus salmeterol or tiotropium plus fluticasonesalmeterol.…”

EMPADE Study: Evaluation of Medical Prescriptions and Adverse Drug Events in COPD Patients Admitted to Intensive Care Unit

“…It is widely acknowledged that LABA/SABA-ICS combination therapy is far better than LABA/SABA mono-therapy in controlling COPD; this combination not only reduces the risk of exacerbations but also improves QOL and airflow measures [16][17][18][19]. Antiinflammatory activity of the combination may help in reducing the risks of re-hospitalization or death [20].…”

Emerging inhaled bronchodilators: an update

“…Looking at the aforementioned trials, it might be argued that it is possible that the type of LABA included in combination with a LAMA might make a difference to the results (table 3) [88].…”

“…The development of once-daily dual-action ultra-LABA/ LAMA combination products may also serve as a basis for improved triple therapy combinations through co-formulation with novel ICSs or novel anti-inflammatory compounds, such as inhaled phosphodiesterase (PDE) 4 inhibitors, that could deliver three complementary therapeutic effects in patients with asthma and, mainly, COPD [7,88,97]. The potential for these therapeutic strategies to be administered once daily simplifies patient treatment regimens and therefore increases the likelihood of compliance with therapy.…”